A German court on Friday ruled that Eli Lilly & Co. cannot prevent a competitor from selling a generic form of its key Alimta cancer drug once the patent expires this December.

Alimta treats mesothelioma, a rare cancer linked to asbestos exposure. It generated 11% of the companyâ€™s total revenue in 2012 and consists of two patents. The compound patent covers the basic chemical composition of the drugs. A second patent covers the...